Clinical Trial Detail

NCT ID NCT02636322
Title A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Vincristine Sulfate

Ibrutinib + Lenalidomide + Rituximab

Prednisone

Age Groups: adult

No variant requirements are available.